Recombinant Anti-CTLA4 antibody [CAL49] (ab237712)
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-344857-CTLA4antibodycal49-immunohistochemistryparaffin-tonsil-human.jpg "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTLA4 antibody [CAL49] (ab237712)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [CAL49] to CTLA4
- Suitable for: IHC-P, Flow Cyt (Intra), WB, IP
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-CTLA4 antibody [CAL49]
See all CTLA4 primary antibodies -
Description
Rabbit monoclonal [CAL49] to CTLA4 -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, Flow Cyt (Intra), WB, IPmore details
Unsuitable for: ICC/IF -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- IHC-P: Human tonsil, lymph node and breast carcinoma tissues. WB: Human PBMCs (treated with 10µg/ml PHA for 2 days) whole cell lysate; mouse splenocytes (treated with 2.5µg/ml Concanavalin A (ConA) for 3 days) whole cell lysate. Flow Cyt (intra): Human PBMCs (treated with 10µg/ml PHA for 2 days); mouse splenocytes (treated with 2.5µg/ml Concanavalin A (ConA) for 3 days). IP: Human tonsil lysate.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.05% Sodium azide
Constituent: PBS -
Concentration information loading... -
Purity
Protein A purified -
Purification notes
Purity >99%. -
Clonality
Monoclonal -
Clone number
CAL49 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab237712 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P | (2) |
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
| Flow Cyt (Intra) |
1/400.
|
|
| WB |
1/1000. Detects a band of approximately 25 kDa (predicted molecular weight: 25 kDa).
|
|
| IP |
1/30.
|
| Notes |
|---|
|
IHC-P
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
|
Flow Cyt (Intra)
1/400. |
|
WB
1/1000. Detects a band of approximately 25 kDa (predicted molecular weight: 25 kDa). |
|
IP
1/30. |
Target
-
Function
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. -
Tissue specificity
Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. -
Involvement in disease
Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.
Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3) [MIM:609755]. It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. -
Sequence similarities
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Post-translational
modificationsN-glycosylation is important for dimerization.
Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. -
Cellular localization
Cell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and. - Information by UniProt
-
Database links
- Entrez Gene: 1493 Human
- Entrez Gene: 100505288 Mouse
- Entrez Gene: 12477 Mouse
- Omim: 123890 Human
- SwissProt: P16410 Human
- SwissProt: P09793 Mouse
- Unigene: 247824 Human
- Unigene: 390 Mouse
-
Alternative names
- ALPS5 antibody
- CD 152 antibody
- CD antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTLA4 antibody [CAL49] (ab237712)
Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling CTLA4 with ab237712 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ready to use. Positive staining on human tonsil is observed. Counter stained with hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) ready to use.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 30 mins.
The section was incubated with ab237712 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument.
-
![Western blot - Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-344856-CTLA4antibodycal49-westernblot-mouse-human.jpg)
Western blot - Anti-CTLA4 antibody [CAL49] (ab237712)All lanes : Anti-CTLA4 antibody [CAL49] (ab237712) at 1/1000 dilution
Lane 1 : Untreated human PBMC (human peripheral blood mononuclear cell) whole cell lysate
Lane 2 : Human PBMC (treated with 10µg/ml PHA for 2 days) whole cell lysate
Lane 3 : Untreated mouse splenocyte whole cell lysate
Lane 4 : Mouse splenocyte (treated with 2.5µg/ml Concanavalin A (ConA) for 3 days) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 25 kDa
Observed band size: 25 kDa
Exposure time: 3 minutesBlocking and dilution buffer: 5% NFDM/TBST.
-
![Flow Cytometry (Intracellular) - Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-344863-CTLA4antibodycal49-flowcytometry-mouse.jpg)
Flow Cytometry (Intracellular) - Anti-CTLA4 antibody [CAL49] (ab237712)Intracellular flow cytometric analysis of2% paraformaldehyde-fixed, 0.1% Tween 20 permeabilized mouse splenocytes (treated with 2.5µg/ml Concanavalin A (ConA) for 3 days) cells labeling CTLA4 with ab237712 at 1/400 (Right) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (Left).
Cells were surface stained with anti-CD3 conjugated to Alexa Fluor® 647. Then fixed with 2% PFA for 10min followed by intracellular staining with rabbit IgG (Left) and ab237712 (Right).
Goat Anti-Rabbit IgG Fc (Alexa Fluor® 488) preadsorbed (ab150097), at 1/2000 dilution was used as the secondary antibody.
-
![Immunoprecipitation - Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-344859-CTLA4antibodycal49-immunoprecipitation-tonsil-human.jpg)
Immunoprecipitation - Anti-CTLA4 antibody [CAL49] (ab237712)CTLA4 was immunoprecipitated from 0.35 mh human tonsil lysate with ab237712 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab237712 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used as secondary antibody at 1/1000 dilution.
Lane 1: Human tonsil lysate 10 μg (Input).
Lane 2: ab237712 IP in human tonsil lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab237712 in human tonsil lysate.Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 30 seconds. -
![Flow Cytometry (Intracellular) - Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-344862-CTLA4antibodycal49-flowcytometry-human.jpg)
Flow Cytometry (Intracellular) - Anti-CTLA4 antibody [CAL49] (ab237712)Intracellular flow cytometric analysis of 2% paraformaldehyde-fixed, 0.1% Tween 20 permeabilized human PBMC (peripheral blood mononuclear cell) (treated with 10µg/ml PHA for 2 days) cells labeling CTLA4 with ab237712 at 1/400 (Right) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (Left).
Cells were surface stained with anti-CD3 conjugated to Alexa Fluor® 647. Then fixed with 2% PFA for 10min followed by intracellular staining with rabbit IgG (Left) and ab237712 (Right).
Goat Anti-Rabbit IgG Fc (Alexa Fluor® 488) preadsorbed (ab150097), at 1/2000 dilution was used as the secondary antibody.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-331813-anti-ctla4-antibody-cal49-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTLA4 antibody [CAL49] (ab237712)Formalin-fixed, paraffin-embedded human breast carcinoma tissue stained for CTLA4 using ab237712 at 0.25 μg/ml in immunohistochemical analysis.
Incubate with primary antibody for 75 minutes at room temperature.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-331812-anti-ctla4-antibody-cal49-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CTLA4 antibody [CAL49] (ab237712)Formalin-fixed, paraffin-embedded human lymph node tissue stained for CTLA4 using ab237712 at 0.25 μg/ml in immunohistochemical analysis.
Incubate with primary antibody for 75 minutes at room temperature.
-
![Anti-CTLA4 antibody [CAL49] (ab237712)](https://www.abcam.com/ps/products/237/ab237712/Images/ab237712-8-benefits-of-recombinant-antibodies.png)
Anti-CTLA4 antibody [CAL49] (ab237712)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab237712 has been referenced in 4 publications.
- Recasens M et al. Chronic exposure to IL-6 induces a desensitized phenotype of the microglia. J Neuroinflammation 18:31 (2021). PubMed: 33482848
- Liu Y et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat Commun 12:741 (2021). PubMed: 33531485
- Dong L et al. High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury. J Inflamm Res 14:2471-2482 (2021). PubMed: 34140795
- Lv Z et al. Elevated mRNA Level of Y-Box Binding Protein 1 Indicates Unfavorable Prognosis Correlated with Macrophage Infiltration and T Cell Exhaustion in Luminal Breast Cancer. Cancer Manag Res 13:6411-6428 (2021). PubMed: 34429650